Pfizer Lung Cancer Drug Fails to Improve Survival in Trial

A clinical trial for Pfizer's lung cancer drug has failed to demonstrate an improvement in patient survival. This outcome marks a setback for the pharmaceutical company's efforts in lung cancer treatment.

23 Jun, 00:00 — 23 Jun, 00:00

Post Share

Sources

Showing 1 of 2 sources

japan-timesMostly Factual70d ago

Pfizer’s lung cancer drug trial fails to boost survival

Patients given the drug, called sigvotatug vedotin, didn't live significantly longer than those given standard therapy.

Read full article →

Coverage Timeline

First report: bloomberg · 22 Jun, 20:37|Full coverage: 2 · 3h|Window: 3h

Left-leaningCenterRight-leaning

bloomberg22 Jun, 20:37First to report

Pfizer’s Lung Cancer Drug Trial Fails to Boost Survival - Bloomberg.com

3h later

japan-times23 Jun, 00:00Latest update

Pfizer Lung Cancer Drug Fails to Improve Survival in Trial

Sources

Pfizer’s lung cancer drug trial fails to boost survival

Coverage Timeline

Pfizer’s Lung Cancer Drug Trial Fails to Boost Survival - Bloomberg.com

Pfizer’s lung cancer drug trial fails to boost survival

Related Stories

Lionel Richie Hospitalized in ICU Following St. Louis Concert

Anna Hazare admitted to Mumbai hospital's ICU with acute dehydration, kidney issue

Ebola Outbreak in Democratic Republic of Congo Surpasses 6,000 Cases

England Pharmacies to Offer Free Quick Cholesterol Screening Tests